Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Initial dual oral therapy improves HbA1c target achievement in early stage type 2 diabetes
Dual Therapy Shows Better Results for Type 2 Diabetes Control
Researchers evaluated the efficacy of initial dual oral therapy compared to monotherapy for patients with early-stage type 2 diabetes. The f…
Starting with two medications instead of one may help people with early type 2 diabetes reach their blood sugar goals more effectively.
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
New management model improves medication use and health for seniors
This randomized controlled trial of 200 older adults with type 2 diabetes and atherosclerotic cardiovascular disease found that a general me…
A new personalized care plan helps older adults with diabetes and heart disease stay on their medications and improve their daily habits.
Finerenone reduces composite cardiovascular death and worsening heart failure events in patients with symptomatic heart failure
Finerenone Reduces Heart Failure Events in Specific Patient Groups
This narrative review evaluates finerenone for patients with symptomatic heart failure and LVEF ≥40%. It finds that finerenone reduces the c…
A new medication called finerenone may help reduce certain heart failure events for adults with specific types of heart muscle function.
SGLT2 inhibitors associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes
SGLT2 inhibitors associated with lower mortality in heart transplant patients
This meta-analysis examined the impact of SGLT2 inhibitor use on outcomes for heart transplant recipients with type 2 diabetes. The authors …
New analysis suggests SGLT2 inhibitors may lower death rates for heart transplant recipients with type 2 diabetes without increasing UTI ris…
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failure
Moderate evidence supports adding SGLT2 inhibitors to heart failure treatment
This systematic review and network meta-analysis evaluated adding SGLT2 inhibitors or angiotensin receptor-neprilysin inhibitors to neurohor…
A large analysis suggests adding SGLT2 inhibitors may lower risk of death or hospitalization for heart failure, though caution is advised.
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
Real-time glucose monitoring improves blood sugar control in type 2 diabetes
This randomised controlled trial compared real-time continuous glucose monitoring against standard self-monitoring of blood glucose in adult…
A new trial shows continuous glucose monitoring helps lower blood sugar levels better than standard finger-prick testing for adults with typ…
SGLT2 and dual SGLT1/2 inhibitors reduce cardiovascular death or heart failure hospitalization risk in type 2 diabetes patients
Three diabetes drugs lower heart failure and heart attack risk
This network meta-analysis evaluates bexagliflozin, ertugliflozin, and sotagliflozin versus placebo for patients with type 2 diabetes. The a…
Three newer diabetes drugs cut heart failure and heart attack risk in people with type 2 diabetes, a new analysis finds.
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
New review shows SGLT2 drugs raise DKA risk when blood sugar is high
This meta-analysis of observational and randomized trials found SGLT2 inhibitor use is associated with an increased risk of diabetic ketoaci…
A big review of many studies found that medicines for diabetes called SGLT2 inhibitors can increase the chance of a serious condition called…